GlassScriptPhysician profile
Jason Thomas Cook
NPI 1538364203
$120,296.22
in general payments reported to CMS, 2019-2025
22 companies · $16K in 2025
The $16K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.36 · 2020: $22K · 2021: $33K · 2022: $19K · 2023: $21K · 2024: $9,146 · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $31K · Consulting Fee: $8,313 · Travel and Lodging: $4,221 · Food and Beverage: $2,410.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $30,500.00 |
| Consulting Fee | $8,312.50 |
| Travel and Lodging | $4,220.57 |
| Food and Beverage | $2,409.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $86,811.17 | 2021-2025 | Ubrelvy, Qulipta |
| Allergan, INC. | $22,836.19 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $9,774.57 | 2020-2021 | |
| Lilly USA, LLC | $146.36 | 2020-2025 | Mounjaro, Zepbound, Reyvow |
| Lundbeck LLC | $112.09 | 2024 | Vyepti |
| Axsome Therapeutics, INC. | $93.54 | 2025 | Symbravo |
| Pfizer INC. | $79.22 | 2021-2025 | |
| Amgen INC. | $75.66 | 2022-2025 | Otezla, Repatha |
| Abbott Laboratories | $48.92 | 2019-2022 | |
| Novo Nordisk INC | $39.20 | 2025 | Ozempic |
| Exact Sciences Corporation | $38.82 | 2025 | The Cologuard Plus Collection Kit |
| Medtronic, INC. | $27.92 | 2024 | Intellis Adaptivestim |
| Corium, LLC | $27.33 | 2025 | Azstarys |
| Radius Health, INC. | $25.45 | 2025 | Tymlos |
| Merck Sharp & Dohme LLC | $25.09 | 2025 | Vaxneuvance, Capvaxive |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $23.58 | 2025 | Rexulti |
| Glaxosmithkline, LLC. | $22.23 | 2025 | Arexvy, Shingrix |
| Teva Pharmaceuticals USA, INC. | $21.69 | 2024 | Ajovy |
| Xeris Pharmaceuticals, INC. | $19.71 | 2025 | Gvoke Hypopen |
| Astellas Pharma US INC | $18.29 | 2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $15.50 | 2022 | |
| Tonix Medicines, INC. | $13.69 | 2024 | Zembrace Symtouch |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Cook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.